Novavax Inc. sell shadow
Start price
27.07.20
/
0%
€110.70
Target price
04.11.21
-
Performance (%)
50.84%
End price
05.11.21
€166.98
Summary
This prediction ended on 05.11.21 with a price of €166.98. The SELL prediction by shadow for Novavax Inc. was trending in the completely wrong direction and closed with a performance of 50.84%.Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novavax Inc. | -4.482% | -4.482% | -51.686% | -97.094% |
| iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
| iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
| iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
| iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
According to shadow what are the pros and cons of Novavax Inc. for the foreseeable future?
Pros
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Good rating
Standard Investments for future growth
Capable Management
Top 10 in its market
Known brand
Future proof or reliable business model
Cons
Probably not worthwhile Investment
High valuation
Low dividend yield expected
negative Cash Flow expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bad culture
Little innovation
Few uniques
Growths slower than the competition
Dependend from some customers or products
Sustainability is little important
high free float
Higher risks for its business
Significant cyclical dependencies
Comments by shadow for this prediction
In the thread Novavax Inc. diskutieren
In the thread Trading Novavax Inc.
Die von shadow gewählte maximale Laufzeit wurde überschritten
Stopped prediction by shadow for Novavax Inc.
Novavax Inc.
Start price
Target price
Perf. (%)
€93.40
07.07.20
07.07.20
€110.00
27.07.20
27.07.20
18.52%
27.07.20
27.07.20
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Probably not worthwhile Investment
High valuation
